Prostate cancer
Education on prostate cancer and Alpha-1 Antitrypsin research hypotheses, with clear separation from urology and oncology standard care.
Research status: Investigational / hypothesis
Research hypothesis, not medical advice
The connections described on this page come from Mark Egly's patent filing and ongoing research. They are not established medical facts. Always work with your physician for diagnosis and treatment.
Research hypothesis. The connection between prostate cancer and Alpha-1 Antitrypsin is described in Mark Egly's 2020 patent filing. This is not established medical fact and is not medical advice. Always talk with your doctor about your own health.
What is prostate cancer?
Prostate cancer is abnormal growth of cells in the prostate gland. Screening, diagnosis, and treatment follow urology and oncology guidelines. The Mark Egly Foundation does not replace cancer care. We focus on Alpha-1 Antitrypsin Deficiency (AATD) education and research questions that may intersect inflammation biology.
Prostate cancer prevention searches
People often look for prostate cancer prevention guidance on diet, screening age, family history, and PSA testing. Those established topics belong with public health and specialty resources. Our page adds a research lens on Alpha-1 Antitrypsin (AAT) biology.
How this may relate to Alpha-1 (hypothesis)
The patent discusses neutrophil elastase (NE) in prostate cancer progression literature and proposes that inadequate AAT may worsen tissue injury and inflammatory pathways. It explores whether maintaining healthier circulating AAT could matter in that biology. That proposal is a research hypothesis, not a proven prevention or treatment path.
What Mark Egly's patent discusses
The filing references scientific discussion of NE promoting prostate cancer progression and describes investigational ideas about controlling neutrophil related tissue infiltration. Independent clinical validation is required before any change to prostate cancer care.
Related pages
What you can do
- Follow your clinician's plan for prostate screening and treatment.
- Learn established AATD facts on What is Alpha-1 Antitrypsin Deficiency.
- Discuss AAT testing if you have unexplained lung or liver disease or a family history of AATD.
- Support research funding.
Sources and references
References checked July 26, 2026
- Alpha-1 antitrypsin deficiency (MedlinePlus Genetics (NIH))Research status: Established clinical knowledge
- American Thoracic Society / European Respiratory Society statements on lung disease (locate current AATD guidance) (American Thoracic Society)Research status: Established clinical knowledgeUse the current ATS/ERS AATD statements applicable to your practice.
- Method of Preventing and/or Treating a Plurality of Diseases (Mark Egly patent disclosure summary) (Mark Egly Foundation patent overview)Research status: Investigational / hypothesisPrimary source for Mark Egly research hypotheses. Not peer-reviewed clinical evidence. Confirm USPTO application number with counsel before citing externally.
Educational content only. Not a diagnosis or treatment plan. Work with your clinician for personal medical decisions.